SCHEMBL26812759

SCHEMBL26812759

CC(C)c1ccccc1-c1cc(Oc2ccccc2F)nc(NS(=O)(=O)c2ccc(N)cc2)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.47
▸ TDP1 Q9NUW8 2/20 0.44
▸ L3MBTL1 Q9Y468 2/20 0.43
▸ SMN1; SMN2 Q16637 3/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ CYP3A4 P08684 1/20 0.42
▸ HTT P42858 2/20 0.39
▸ MEN1 O00255 2/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ LMNA P02545 3/20 0.39
▸ HTR1A P08908 1/20 0.39
▸ HTR7 P34969 1/20 0.39
▸ AURKA O14965 2/20 0.37
▸ TSHR P16473 2/20 0.37
▸ DHFR P00374 1/20 0.37
▸ CHEK1 O14757 1/20 0.37
▸ JAK2 O60674 1/20 0.37
▸ ABL1 P00519 1/20 0.37
▸ NTRK1 P04629 1/20 0.37
▸ CSF1R P07333 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29567103 1.00 MAPT (0.47) MAPTTDP1L3MBTL1SMN1; SMN2ALDH1A1
SCHEMBL24309354 0.92 TDP1 (0.45) MAPTTDP1SMN1; SMN2ALDH1A1HTT
SCHEMBL29567008 0.92 TDP1 (0.45) MAPTTDP1SMN1; SMN2ALDH1A1HTT
SCHEMBL26812870 0.92 TDP1 (0.47) MAPTTDP1L3MBTL1SMN1; SMN2ALDH1A1
SCHEMBL26806777 0.91 TDP1 (0.40) MAPTTDP1SMN1; SMN2ALDH1A1HTT
SCHEMBL29566577 0.91 TDP1 (0.47) MAPTTDP1SMN1; SMN2ALDH1A1HTT
SCHEMBL26812772 0.91 TDP1 (0.47) MAPTTDP1SMN1; SMN2ALDH1A1HTT
SCHEMBL26812864 0.91 TDP1 (0.44) MAPTTDP1ALDH1A1HTTMEN1
SCHEMBL24310180 0.90 TDP1 (0.44) TDP1SMN1; SMN2ALDH1A1HTTMEN1
SCHEMBL29566852 0.90 TDP1 (0.44) TDP1SMN1; SMN2ALDH1A1HTTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B MAPT 4864/4885TDP1 4534/4885L3MBTL1 4300/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback